AYTU — Aytu Biopharma Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousMicro CapTurnaround

Annual income statement for Aytu Biopharma, fiscal year end - June 30th, USD millions except per share, conversion factor applied.

	2021 June 30th	R2022 June 30th	2023 June 30th	R2024 June 30th	2025 June 30th
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	65.6	96.7	107	65.2	66.4
Cost of Revenue
Gross Profit	29.2	52.3	66.6	49.1	45.8
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	126	206	124	67.4	74.2
Operating Profit	-60.4	-110	-17.1	-2.19	-7.83
Total Net Non Operating Interest Income / Expense
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-58	-109	-17.1	-10.4	-13.7
Provision for Income Taxes
Net Income After Taxes	-58.3	-109	-17.1	-12.5	-14.2
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	-58.3	-109	-17.1	-15.8	-13.6
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-58.3	-109	-17.1	-15.8	-13.6
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-52.4	-40.7	-3.4	-1.8	-1.15